David Shelton - Chemours Senior Vice President, General Counsel, Secretary

CC Stock  USD 28.71  0.19  0.66%   

President

Mr. David Charles Shelton has appointed as Senior Vice President, Corporationrationrate Secretary and General Counsel of the Company with effect on July1, 2015. In 2011, Mr. Shelton was appointed Associate General Counsel, DuPont, and was responsible for the US Commercial team the business lawyers and paralegals counseling all the DuPont business units with the exception of Agriculture. Mr. Shelton was the Commercial attorney to a variety of DuPont businesses including the Performance Materials platform, which he advised on international assignment in Geneva, and the businesses now comprising the DuPont Chemicals and Fluoroproducts business unit. Prior to that, Mr. Shelton advised the company on environmental and remediation matters as part of the environmental legal team. Mr. Shelton joined DuPont in 1996, after seven years in private practice as a litigator in Pennsylvania and New Jersey. since 2015.
Age 57
Tenure 9 years
Address 1007 Market Street, Wilmington, DE, United States, 19801
Phone302 773 1000
Webhttps://www.chemours.com

Chemours Management Efficiency

The company has Return on Asset (ROA) of 0.0457 % which means that for every $100 of assets, it generated a profit of $0.0457. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.333) %, which implies that it produced no returns to current stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. The current year's Return On Capital Employed is expected to grow to -0.01. At present, Chemours' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 2.11, whereas Total Assets are forecasted to decline to about 7.5 B.
The company reports 4.3 B of total liabilities with total debt to equity ratio (D/E) of 2.94, which may imply that the company relies heavily on debt financing. Chemours has a current ratio of 1.78, which is generally considered normal. Debt can assist Chemours until it has trouble settling it off, either with new capital or with free cash flow. So, Chemours' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Chemours sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Chemours to invest in growth at high rates of return. When we think about Chemours' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Russell GordonRPM International
58
Joseph BerquistQuaker Chemical
53
Anne SchumannAshland Global Holdings
58
John ManningSensient Technologies
55
Wilbert PlatzerQuaker Chemical
63
Joseph MatrangeQuaker Chemical
74
Edward MooreRPM International
67
Lonny DiRussoRPM International
59
Keith SilvermanAshland Global Holdings
51
Sean LannonAxalta Coating Systems
45
John WillisAshland Global Holdings
59
Nicholas SwykaSelect Energy Services
43
Gordon HydeRPM International
57
Michael SkarkeSelect Energy Services
42
Curtis EspelandEastman Chemical
56
Michelle StewartEastman Chemical
52
Robert RoopAxalta Coating Systems
N/A
Clark JordanEastman Chemical
59
Brad LichEastman Chemical
56
Jonathan HastingsMinerals Technologies
61
Yvonne MohrenfelsAshland Global Holdings
58
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. Chemours operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. It employs 6400 people. Chemours Co (CC) is traded on New York Stock Exchange in USA. It is located in 1007 Market Street, Wilmington, DE, United States, 19801 and employs 6,200 people. Chemours is listed under Diversified Chemicals category by Fama And French industry classification.

Management Performance

Chemours Leadership Team

Elected by the shareholders, the Chemours' board of directors comprises two types of representatives: Chemours inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemours. The board's role is to monitor Chemours' management team and ensure that shareholders' interests are well served. Chemours' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemours' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dawn Farrell, Independent Chairman of the Board
Curtis Anastasio, Independent Director
Jonathan Lock, Senior Vice President and Chief Development Officer
Amber Wellman, Chief Officer
Matthew Abbott, Vice President - Digital and Analytics Platforms Leader
David Shelton, Senior Vice President, General Counsel, Secretary
Denise Dignam, President - Advanced Performance Materials
Curtis Crawford, Independent Director
Aditya Beri, Interim Business
Mary Cranston, Independent Director
Bradley Bell, Independent Director
Sheryl Telford, Chief Sustainability Officer
Ron Charles, Senior People
Erin Kane, Independent Director
Alisha Bellezza, President - Thermal & Specialized Solutions
Joseph Martinko, President Solutions
Susan Kelliher, Senior Vice President – Human Resources and Health Services
Gerardo Calderon, President Materials
Eugene Snell, President - Titanium Technologies
Sandra Rogers, Independent Director
Kurt Bonner, Ma Relations
Kristine Wellman, General VP
Sean Keohane, Independent Director
Sameer Ralhan, Chief Financial Officer, Senior Vice President, Treasurer
Guillaume Pepy, Independent Director
Brandon Ontjes, Vice Relations
Camela Wisel, Chief Accounting Officer, Vice President Controller
Mark Newman, Chief Operating Officer, Senior Vice President
Edwin Sparks, President - Chemical Solutions Business, Titanium Technologies
Erich Parker, Senior Vice President of Corporate Communications and Chief Brand Officer.
Mark Vergnano, President, Chief Executive Officer, Director
Richard Brown, Independent Chairman of the Board
Alvenia Scarborough, Senior Vice President - Corporate Communications and Chief Brand Officer

Chemours Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemours a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Chemours

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemours position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemours will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Chemours could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chemours when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chemours - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chemours Co to buy it.
The correlation of Chemours is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chemours moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chemours moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chemours can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Chemours offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemours' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemours Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemours Co Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Chemours information on this page should be used as a complementary analysis to other Chemours' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Chemours Stock analysis

When running Chemours' price analysis, check to measure Chemours' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemours is operating at the current time. Most of Chemours' value examination focuses on studying past and present price action to predict the probability of Chemours' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemours' price. Additionally, you may evaluate how the addition of Chemours to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Chemours' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.65)
Dividend Share
1
Earnings Share
(2.22)
Revenue Per Share
39.222
Quarterly Revenue Growth
(0.12)
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.